The Company's broad platform technology for dendritic cell-based vaccines is currently being tested in an ongoing 240-patient Phase II clinical trial for newly diagnosed Glioblastoma multiforme ("GBM") -- the most aggressive and lethal form of brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers. The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.
Dr. Maida joined the Company in June, 2011, as Chief Operating Officer ("COO"), bringing more than 20 years' experience in building oncology companies, with expertise in the business, financial, clinical and regulatory aspects of oncology products, as well as the underlying science. Over these two decades, Dr. Maida has held positions as Chairman, CEO, COO, CSO, CFO and VP Business Development, and has raised nearly $200 million in financings for oncology companies. Among these experiences, he served as CEO of CancerVax, an early leader in cancer vaccines. In that role, he raised the company's first $30 million of funding, and was responsible for conducting multi-hundred patient, multi-center clinical trials with the company's cancer vaccines. Prior to joining NORTHWEST BIO, Dr. Maida was serving as Global Head of Oncology for a leading contract research organiz
|SOURCE Northwest Biotherapeutics|
Copyright©2010 PR Newswire.
All rights reserved